Every 10-Q that EMMAUS LIFE SCIENCES INC (EMMA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EMMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EMMA filings page.
Emmaus Life Sciences, Inc. reported a sharp improvement in results for the quarter ended June 30, 2026. Net revenues rose to $6.3 million from $2.8 million a year earlier, driven mainly by U.S. Endari® sales and a new license and supply relationship with NeoImmuneTech (NIT). Quarterly net income was $1.3 million, compared with a net loss of $1.1 million in the prior-year quarter, while the first half still showed a net loss of $2.0 million.
Despite better operating performance, the balance sheet remains highly leveraged. Cash and cash equivalents were $2.8 million and total assets $16.4 million, against total liabilities of $82.5 million and a stockholders’ deficit of $66.2 million. The company discloses a working capital deficit of $60.1 million and significant notes payable and convertible debt, along with pledged investments and "sale of future receipts" financing arrangements.
Management states there is substantial doubt about the ability to continue as a going concern over the next 12 months without restructuring or refinancing existing indebtedness and raising additional capital, noting that no such arrangements are currently in place.
Emmaus Life Sciences reported a challenging quarter for the three months ended March 31, 2026. Revenue was $1.98 million, down from $2.41 million a year earlier, while net loss widened to $3.34 million from $2.33 million. Basic and diluted loss per share was $0.05 on 70.2 million weighted-average shares.
Total assets were $18.7 million against total liabilities of $86.6 million, resulting in a stockholders’ deficit of $67.9 million and cash of only $1.07 million. Management discloses a working capital deficit of $64.5 million and states there is substantial doubt about the company’s ability to continue as a going concern without restructuring debt or raising additional capital.
U.S. Endari® revenue declined sharply, partially offset by growth in international sales. The company continues to rely on high-interest debt, convertible notes and related‑party loans while managing a sizeable convertible bond investment in Telcon. Subsequent to quarter end, its U.S. Endari® license and supply arrangements with NeoImmuneTech became effective, shifting future U.S. revenue toward supply sales and royalties.
Emmaus Life Sciences filed its Q3 2025 10-Q, highlighting a sharp revenue decline and liquidity strain alongside a going concern warning. Q3 revenue was $3.38 million versus $5.48 million a year ago, and the company posted a net loss of $2.08 million versus net income of $1.83 million in Q3 2024. Operating profit of $0.70 million was outweighed by other expense of $2.19 million, driven mainly by interest expense of $1.93 million.
For the nine months, revenue was $8.60 million versus $13.36 million. Cash was $0.29 million with current liabilities of $64.17 million, and total liabilities of $80.24 million against assets of $20.76 million, resulting in a stockholders’ deficit of $59.49 million. Management states there is substantial doubt about continuing as a going concern without restructuring debt and raising additional financing. The company also recorded a $0.53 million realized loss year‑to‑date on its Telcon convertible bond.